Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Twenty Years of G-CSF
Granulocyte colony-stimulating factor (G-CSF or GCSF) is a secreted glycoprotein that stimulates the proliferation and differentiation of granulocyte precursor cells, and induces mobilization of peripheral blood progenitor cells from the bone marrow. Development of recombinant human G-CSF has had a profound impact on the treatment of many diseases, including severe chronic neutropenia and cancer, and has enabled peripheral stem cell transplantation to supplant bone marrow transplantation in the autologous setting. This Milestones in Drug Therapy volume describes the experience of the last 20 years of treatment with recombinant human G-CSF, including the basic science, the use of recombinant human G-CSF in both the oncology and nononcology settings, and the safety and economics of its use. Many of the authors were the original investigators of recombinant human G-CSF and other authors are key researchers who provide their outlook for the next 20 years for use of and research with recombinant human G-CSF.
Durability of Composites in a Marine Environment
Composites are widely used in marine applications. There is considerable experience of glass reinforced resins in boats and ships but these are usually not highly loaded. However, for new areas such as offshore and ocean energy there is a need for highly loaded structures to survive harsh conditions for 20 years or more. High performance composites are therefore being proposed. This book provides an overview of the state of the art in predicting the long term durability of composite marine structures. The following points are covered: • Modelling water diffusion • Damage induced by water • Accelerated testing • Including durability in design • In-service experience. This is essential reading for all those involved with composites in the marine industry, from initial design and calculation through to manufacture and service exploitation. It also provides information unavailable elsewhere on the mechanisms involved in degradation and how to take account of them. Ensuring long term durability is not only necessary for safety reasons, but will also determine the economic viability of future marine structures.
Frontiers in Chemistry: 10 Years Anniversary
We are delighted to present the inaugural edition of the article collection, “10 years with Frontiers in Chemistry"*. This collection celebrates high-impact, authoritative and accessible articles covering the most topical research at the forefront of the chemical sciences in honor of Frontiers 10th anniversary. The collection contains works encompassing all of our nineteen sections in Frontiers in Chemistry. Each article was selected by the nomination of our Field Chief Editor, Prof Steve Suib in recognition of the author’s prominence and influence in their respective field, or by virtue of their reputation in the research community. The cutting-edge work presented in this article collec...
Gas Transport in Glassy Polymers
This Special Issue of Membranes focuses on several new aspects of fluid transport in glassy polymers, with application in relevant membrane separations such as gas purification, VOC removal and CO2 capture. In particular, the focus lies on novel experimental techniques, and detailed characterization of specific phenomena like polar and multicomponent interactions during transport. The properties of novel materials, such as mixed matrix membranes based on glassy polymers and different selective fillers, are also presented. A critical review of existing modeling approaches to describe the sorption and transport in glassy polymers suitable for membrane separations is provided, including both macroscopic and atomistic models, and relying both on the standard solution–diffusion process and on the facilitated transport mechanism.
Frontiers in Chemistry: Rising Stars
The Frontiers in Chemistry Editorial Office team are delighted to present the inaugural “Frontiers in Chemistry: Rising Stars” article collection, showcasing the high-quality work of internationally recognized researchers in the early stages of their independent careers. All Rising Star researchers featured within this collection were individually nominated by the Journal’s Chief Editors in recognition of their potential to influence the future directions in their respective fields. The work presented here highlights the diversity of research performed across the entire breadth of the chemical sciences, and presents advances in theory, experiment and methodology with applications to co...
The Biology and Treatment of Myeloid Leukaemias
This book is a printed edition of the Special Issue "The Biology and Treatment of Myeloid Leukaemias" that was published in IJMS
Drug Resistance in Leukemia &
The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols.
Novel Agents for Multiple Myeloma
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. It accounts for approximately 1.8% of all hematologic and solid cancers and slightly > 15% of hematologic malignancies in the United States. MM is typically sensitive to different classes of cytotoxic drugs, both as frontline treatment and as treatment for relapsed disease. Unfortunately, even if responses are typically durable, nowadays MM is not considered curable with current approaches. However, MM survival rates have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune-modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation.
